News

Amid ongoing shifts in the global pharmaceutical market — including increasing regulatory scrutiny, raw material shortages, and evolving geopolitical tensions — the industry continues to navigate a landscape of uncertainty. In 2024, global API prices have largely trended downward, with QYOBO’s platform tracking these changes for thousands of APIs, excipients, intermediates and chemicals. This analysis describes API price fluctuations, highlights shifts across therapeutic categories, and provides AI-driven price forecasts for the coming months.

The API market is evolving rapidly, with regulatory approvals on the rise and manufacturing shifting towards Asia. Over the past five years, USDMF and CEP approvals have grown significantly, reflecting increasing demand for APIs in key therapeutic areas. India and China have emerged as dominant players, reshaping the industry landscape. What do these trends mean for the future of pharmaceutical manufacturing? Explore our latest insights.

FDA drug approvals serve as the pulse of pharmaceutical innovation. Between 2015 and 2024, the FDA approved 462 new drugs – a 69% increase from the previous decade. However, annual growth has slowed, indicating that investments in drug development are outpacing new approvals.